-
Mashup Score: 21EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth - 2 month(s) ago
AbstractThe limited efficacy of currently approved immunotherapies in EGFR-driven lung adenocarcinoma (LUAD) underscores the need to better understand alternative mechanisms governing local immunosuppression to fuel novel therapies. Elevated surfactant and GM-CSF secretion from the transformed epithelium induces tumor-associated alveolar macrophage (TA-AM) proliferation, which supports tumor growth by rewiring inflammatory functions and lipid metabolism. TA-AM properties are driven by increased GM-CSF–PPARγ signaling and inhibition of airway GM-CSF or PPARγ in TA-AMs suppresses cholesterol efflux to tumor cells, which impairs EGFR phosphorylation and restrains LUAD progression. In the absence of TA-AM metabolic support, LUAD cells compensate by increasing cholesterol synthesis, and blocking PPARγ in TA-AMs simultaneous with statin therapy further suppresses tumor progression and increases proinflammatory immune responses. These results reveal new therapeutic combinations for immunother
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 21EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth - 2 month(s) ago
AbstractThe limited efficacy of currently approved immunotherapies in EGFR-driven lung adenocarcinoma (LUAD) underscores the need to better understand alternative mechanisms governing local immunosuppression to fuel novel therapies. Elevated surfactant and GM-CSF secretion from the transformed epithelium induces tumor-associated alveolar macrophage (TA-AM) proliferation, which supports tumor growth by rewiring inflammatory functions and lipid metabolism. TA-AM properties are driven by increased GM-CSF–PPARγ signaling and inhibition of airway GM-CSF or PPARγ in TA-AMs suppresses cholesterol efflux to tumor cells, which impairs EGFR phosphorylation and restrains LUAD progression. In the absence of TA-AM metabolic support, LUAD cells compensate by increasing cholesterol synthesis, and blocking PPARγ in TA-AMs simultaneous with statin therapy further suppresses tumor progression and increases proinflammatory immune responses. These results reveal new therapeutic combinations for immunother
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet-
From the March issue— EGFR-driven Lung #Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth, by Alexandra Kuhlmann-Hogan, Christian Metallo, @politikaterina @Tcellogic et al. https://t.co/Xhee65xz1Q @salkinstitute @YaleCancer https://t.co/ab7295Qzrh
-
-
Mashup Score: 0Incidence Trends and Survival in Early-Onset Esophagogastric Adenocarcinoma: A Swedish Population-Based Cohort Study - 10 month(s) ago
AbstractBackground:. Early-onset adenocarcinomas of different sites are increasing in high-income countries, data on esophagogastric adenocarcinoma are sparse.Methods:. We performed a Swedish population-based cohort study over 1993 to 2019 to delineate differences in incidence and survival in early-onset (age 20–54 years) compared with later-onset (55–99 years) esophageal, cardia, and noncardia gastric adenocarcinoma. Temporal incidence trends were quantified as annual percentage changes (APC) and survival differences as excess mortality rate ratios (EMRR) using Poisson regression and including 95% confidence intervals (CI).Results:. Among 27,854 patients with esophagogastric adenocarcinoma, 2,576 were early-onset whereof 470 were esophageal, 645 were cardia, and 1,461 were noncardia gastric. Except noncardia gastric, the male predominance was larger in early-onset compared with later-onset disease. Advanced stage and signet ring cell morphology were more common among early-onset patie
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: Early-onset #adenocarcinomas are increasing in high-income countries. Comparison of early & later-onset Esophagogastric Adenocarcinoma in Sweden finds no major differences in incidence trends. Survival was better in early-onset cancer patients. https://t.co/QkROA7v8yT
-
-
Mashup Score: 0Incidence Trends and Survival in Early-Onset Esophagogastric Adenocarcinoma: A Swedish Population-Based Cohort Study - 10 month(s) ago
AbstractBackground:. Early-onset adenocarcinomas of different sites are increasing in high-income countries, data on esophagogastric adenocarcinoma are sparse.Methods:. We performed a Swedish population-based cohort study over 1993 to 2019 to delineate differences in incidence and survival in early-onset (age 20–54 years) compared with later-onset (55–99 years) esophageal, cardia, and noncardia…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Early-onset #adenocarcinomas are increasing in high-income countries. Comparison of early & later-onset Esophagogastric Adenocarcinoma in Sweden finds no major differences in incidence trends. Survival was better in early-onset cancer patients. https://t.co/JymNQ6v2bg
-
-
Mashup Score: 0Source: link.springer.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Solid Attenuation Components Attention Deep Learning Model to Predict #Micropapillary and Solid Patterns in Lung #Adenocarcinomas on Computed Tomography https://t.co/rdqF12hM2p #VisualAbstract @McMastersKelly https://t.co/H5a7l6hrw3
-
-
Mashup Score: 2Shifts in the Proportion of Distant Stage Early-Onset Colorectal Adenocarcinoma in the United States - 2 year(s) ago
AbstractBackground:. Carcinoids, frequently classified as “colorectal cancer” contribute to rising early-onset colorectal cancer (EOCRC) incidence rates (IR) and have distinct staging distributions compared to often advanced stage adenocarcinomas (screening target). Thus, assessing temporal shifts in early-onset distant stage adenocarcinoma can impact public health.Methods:. 2000–2016…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Montminy et al study how proportions of early-onset distant stage colorectal #adenocarcinomas are changing over time and find the greatest burden in the youngest patients and in Black and Hispanic subgroups. https://t.co/9dtl24gj0o https://t.co/glIYZdkAjF
-
-
Mashup Score: 5Genomic Landscape of Appendiceal Neoplasms - 2 year(s) ago
Purpose Appendiceal neoplasms are heterogeneous and are often treated with chemotherapy similarly to colorectal cancer (CRC). Genomic profiling was performed on 703 appendiceal cancer specimens to compare the mutation profiles of appendiceal subtypes to CRC and other cancers, with the ultimate aim to identify potential biomarkers and novel therapeutic targets. Methods Tumor specimens were…
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
❓/discussion for my #GIOncology #PrecisionOncology colleagues. What have you found helpful in treating #AppendixCancer #Appendiceal #Cancer; both for #LAMN & #Adenocarcinomas? Any actionable targets or approaches? I found this in @JCOPO_ASCO @ASCO https://t.co/TvEBQ51Yit #CRCSM https://t.co/XPfixdBgPq
-
-
Mashup Score: 0Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib - 3 year(s) ago
No targeted treatments are currently approved for HER2 exon 20 insertion–mutant lung adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase inhibitor (TKI) designed to target human epidermal growth factor receptor 2 ( HER2/ERBB2 ) exon 20 insertion mutations. However, the function of mobocertinib on HER2 exon 20 insertion–mutant lung cancer is still unclear. Here…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Study of pre-clinical models by Han et al to elucidate the activity profile of #TyrosineKinaseInhibitor #mobocertinib against HER2 exon 20 insertions in lung #adenocarcinomas shows potent inhibitory activity. https://t.co/ilQiEVondp @mjfitzgera @KwanTang5 https://t.co/qG3YfvAgIZ
-
-
Mashup Score: 0Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib - 3 year(s) ago
No targeted treatments are currently approved for HER2 exon 20 insertion-mutant lung adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase inhibitor (TKI) designed to target human epidermal growth factor receptor 2 (HER2/ERBB2) exon 20 insertion mutations. However, the function of mobocertinib on HER2 exon 20 insertion-mutant lung cancer is still unclear. Here…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Study of pre-clinical models by Han et al to elucidate the activity profile of #TyrosineKinaseInhibitor #mobocertinib against HER2 exon 20 insertions in lung #adenocarcinomas shows potent inhibitory activity. https://t.co/M8sT5686CS @mjfitzgera @KwanTang5 https://t.co/J0WyQLpP1i
-
-
Mashup Score: 0Colon Cancer | Sidney Kimmel Cancer Center - 3 year(s) ago
Cancer Care 360 at the Sidney Kimmel Cancer Center in Philadelphia is a comprehensive circle of care – research, treatment and support – with you in the center.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
DYK that most colorectal cancers are #adenocarcinomas? Learn more this Colorectal Cancer Awareness Month with some FAQs on our website: https://t.co/HnobBxz5Ho #colorectalcancer #coloncancer #rectalcancer #crcsm https://t.co/Cwq8AYC5G5
-
From the March issue— EGFR-driven Lung #Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth, by Alexandra Kuhlmann-Hogan, Christian Metallo, @politikaterina @Tcellogic et al. https://t.co/Xhee65xz1Q @salkinstitute @YaleCancer https://t.co/ab7295Qzrh